Acta Diabetologica最新文献

{"title":"Dose-dependent renoprotection efficacy of sglt2 inhibitors in type 2 diabetes: systematic review and network meta-analysis","authors":"Naveen C. Hegde,&nbsp;Ankit Kumar,&nbsp;Amol N. Patil,&nbsp;Samiksha Bhattacharjee,&nbsp;Nanda Gamad,&nbsp;Kripa Shanker Kasudhan,&nbsp;Vivek Kumar,&nbsp;Ashu Rastogi","doi":"10.1007/s00592-023-02126-8","DOIUrl":"10.1007/s00592-023-02126-8","url":null,"abstract":"<div><h3>Aim</h3><p>To compare the relative effects of different dosages of sodium-glucose cotransport inhibitors (SGLT2i) for renoprotection in Type 2 diabetes mellitus.</p><h3>Methods</h3><p>The study searched different databases (PubMed, Embase, Scopus, and Web of Science) for studies comparing dose-dependent renoprotective efficacy defined as a decline in eGFR with the different “-flozins namely Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Ipragliflozin, Luseogliflozin, Remogliflozin and Sotagliflozin. The studies were compared with the Bayesian approach of network meta-analysis coupled with the random-effect model using the Cochrane risk of bias tool (RoB 2.0), and the surface under the cumulative ranking curve (SUCRA) score was allotted to each dosage of different SGLT-2i.</p><h3>Results</h3><p>A total of 43,434 citations were identified, out of which forty-five randomized trials with 48,067 patients, mentioning the flozin dose and eGFR as an endpoint, were found to be eligible for further analysis. The median duration of the follow-up in the trials was 12 months (IQR 5.5–16 months). Canagliflozin 100 mg demonstrated distinct eGFR benefit with an odds ratio of 2.3 (CI 0.72–3.9) compared to placebo. A statistically non-significant eGFR benefit was observed with all other “-flozins.” Canagliflozin 100 mg drug dose category showed the highest sucra rank probability score of 93%, followed by the Canagliflozin 300 mg and Dapagliflozin 5 mg with sucra rank probability scores of 69% and 65%, respectively. The Flozin-dose assessment against eGFR was similar to the albumin-creatinine ratios as the secondary endpoint in the SUCRA ranking.</p><h3>Conclusion</h3><p>The renoprotective efficacy of SGLT2i is independent of the incremental doses suggesting lower doses may suffice for renal outcomes.</p></div>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 10","pages":"1311 - 1331"},"PeriodicalIF":3.8,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10101538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is hyperinsulinemia a possible clinical explanation underlying the myth of Erysichthon?","authors":"Arthur Saniotis","doi":"10.1007/s00592-023-02108-w","DOIUrl":"10.1007/s00592-023-02108-w","url":null,"abstract":"<div><h3>Background</h3><p>An insulinoma is an endocrine tumor of the pancreas, originating from the beta cells, and has a prevalence of 4 cases per 1 million patients. Insulinomas often follow a “90% rule”: 90% are benign [1, 2], 90% originate in the pancreas, 90% are approximately 2 cm wide, and 90% are isolated. Individuals with an insulinoma may have episodic bouts of hyperinsulinemic hypoglycemia. Typically, an insulinoma is indicated by hypoglycemic symptoms which are a result of catecholamine reaction and neuroglycopenia. There is increased secretion of insulin in patients with an insulinoma despite having lower glucose levels.</p><h3>Purpose</h3><p>This paper examines the myth of Erysichthon and speculates whether the symptoms experienced by him are possibly related to those found in patients with an hyperinsulinoma.</p><h3>Methods</h3><p>The myth of Erysichthon was taken from various sources (i.e. Hesiod, Callimachus, Ovid) and examined. Symptoms of Erysichthon were then examined.</p><h3>Results</h3><p>The myth of Erysichthon depicts various sympathoadrenal and neuroglycopenic symptoms including anxiety and abnormal behaviour which can be found in insulinomas. Insulinomas may often present a diagnostic challenge due to their deceptive nature and overlapping symptoms with other disorders such as neurologic disease. Insulinomas inducing weight loss resemble Calamachus’s account of Erysichthon whose body is finally emaciated, even though having polyphagia.</p><h3>Conclusion</h3><p>The myth of Erysichthon provides an interesting range of clinical symptoms which I have argued relate to symptoms found in patients with an insulinoma. Although, insulinomas were unknown in ancient medical lore, this paper has speculated that based on Erysichthon’s symptoms, the possibility of an insulinoma cannot be ruled out.</p></div>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 9","pages":"1279 - 1282"},"PeriodicalIF":3.8,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00592-023-02108-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9967606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MODY in China: two families carrying the KCNJ11 E229K variant","authors":"Banghui Xiao,&nbsp;Hongmei Yi,&nbsp;Miao Zhang,&nbsp;Rui Wang,&nbsp;Ying Hu,&nbsp;Yi Xu,&nbsp;Zhijuan Shao,&nbsp;Song Zhang,&nbsp;Nianchun Peng","doi":"10.1007/s00592-023-02114-y","DOIUrl":"10.1007/s00592-023-02114-y","url":null,"abstract":"","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 9","pages":"1287 - 1289"},"PeriodicalIF":3.8,"publicationDate":"2023-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10038537","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comprehensive retinal vascular measurements: time in range is associated with peripheral retinal venular calibers in type 2 diabetes in China","authors":"Guohong Zhao,&nbsp;Xiayu Xu,&nbsp;Xinwen Yu,&nbsp;Fei Sun,&nbsp;Aili Yang,&nbsp;Yuxin Jin,&nbsp;Jing Huang,&nbsp;Jing Wei,&nbsp;Bin Gao","doi":"10.1007/s00592-023-02120-0","DOIUrl":"10.1007/s00592-023-02120-0","url":null,"abstract":"<div><h3>Aim</h3><p>Retinal vascular parameters are biomarkers of diabetic microangiopathy. We aimed to investigate the relationship between time in range (TIR) assessed by continuous glucose monitoring (CGM) and retinal vascular parameters in patients with type 2 diabetes in China.</p><h3>Methods</h3><p>The TIR assessed by CGM and retinal photographs were obtained at the same time from adults with type 2 diabetes who were recruited. Retinal vascular parameters were extracted from retinal photographs by a validated fully automated computer program, and TIR was defined as between 3.9–7.8 mmol/L over a 24-h period. The association between TIR and caliber of retinal vessels distributed in different zones were analyzed using multivariable linear regression analyses.</p><h3>Results</h3><p>For retinal vascular parameters measurements, the peripheral arteriovenous and middle venular calibers widen with decreasing TIR quartiles (<i>P</i> &lt; 0.05). Lower TIR was associated with wider peripheral venule after adjusting for potential confounders. Even after further correction for GV, there was still a significant correlation between TIR and peripheral vascular calibers (CV: β = − 0.015 [− 0.027, − 0.003], <i>P</i> = 0.013; MAGE: β = − 0.013 [− 0.025, − 0.001], <i>P</i> = 0.038) and SD: β = − 0.013 [− 0.026, − 0.001], <i>P</i> = 0.004). Similar findings were not found for the middle and central venular calibers or arterial calibers located in different zones.</p><h3>Conclusions</h3><p>The TIR was associated with adverse changes to peripheral retinal venules but not central and middle vessels in patients with type 2 diabetes, suggesting that peripheral retinal vascular calibers may be affected by glycemic fluctuations earlier.</p></div>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 9","pages":"1267 - 1277"},"PeriodicalIF":3.8,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00592-023-02120-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9962963","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AWARE A novel web application to rapidly assess cardiovascular risk in type 2 diabetes mellitus","authors":"Cesare Berra,&nbsp;Roberto Manfrini,&nbsp;Marco Mirani,&nbsp;Loredana Bucciarelli,&nbsp;Ahmed S. Zakaria,&nbsp;Sara Piccini,&nbsp;Renata Ghelardi,&nbsp;Maria Elena Lunati,&nbsp;Sylka Rodovalho,&nbsp;Francesco Bifari,&nbsp;Paolo Fiorina,&nbsp;Franco Folli","doi":"10.1007/s00592-023-02115-x","DOIUrl":"10.1007/s00592-023-02115-x","url":null,"abstract":"<div><h3>Aim</h3><p>To describe the development of the AWARE App, a novel web application for the rapid assessment of cardiovascular risk in Type 2 Diabetes Mellitus (T2DM) patients. We also tested the feasibility of using this App in clinical practice.</p><h3>Methods</h3><p>Based on 2019 European Society of Cardiology/European Association for the Study of Diabetes criteria for cardiovascular risk stratification in T2DM, the AWARE App classifies patients into very high (VH_CVR), high (H_CVR) and moderate (M_CVR) cardiovascular risk categories. In this retrospective clinical study, we employed the App to assess the cardiovascular risk of T2DM patients, while also collecting data about current glycaemic control and pharmacological treatment.</p><h3>Results</h3><p>2243 T2DM consecutive patients were evaluated. 72.2% of the patients were VH_CVR, 8.9% were H_CVR, 0.8% were M_CVR while 18.2% did not fit into any of the risk categories and were classified as “moderate-to-high” (MH_CVR). Compared with the other groups, patients with VH_CVD were more frequently ≥ 65 years old (68.9%), with a longer disease duration (≥ 10 years [56.8%]), a history of cardiovascular disease (41.4%), organ damage (35.5%) and a higher numbers of cardiovascular risk factors. Patients with MH_CVD generally had disease duration &lt; 10 years (96%), younger age (50–60 years [55%]), no history of cardiovascular disease, no organ damage, and 1–2 cardiovascular risk factors (89%). Novel drugs such as Glucagon Like Peptyde 1 Receptor Agonists or Sodium-Glucose Linked Transporter 2 inhibitors were prescribed only to 26.3% of the patients with VH_CVR and to 24.7% of those with H_CVR. Glycaemic control was unsatisfactory in this patients population (HbA1c 7.5 ± 3.4% [58.7 ± 13.4 mmol/mol]).\u0000</p><h3>Conclusions</h3><p>The AWARE App proved to be a practical tool for cardiovascular risk stratification of T2DM patients in real-world clinical practice.\u0000</p></div>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 9","pages":"1257 - 1266"},"PeriodicalIF":3.8,"publicationDate":"2023-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00592-023-02115-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9970126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Nobel Prize of Physiology or Medicine, 1923: controversies on the discovery of the antidiabetic hormone","authors":"Alberto de Leiva-Hidalgo,&nbsp;Alejandra de Leiva-Pérez","doi":"10.1007/s00592-023-02098-9","DOIUrl":"10.1007/s00592-023-02098-9","url":null,"abstract":"<div><h3>Aims</h3><p>To analyze the main contributions to the discovery of the antidiabetic hormone in the period between <u>1889</u>, the year in which Oskar Minkowski demonstrated that complete pancreatectomy in dogs caused diabetes, and the year 1923, the date in which the clinical use of insulin was consolidated. A main objective has been to review the controversies that followed the Nobel Prize and to outline the role of the priority rule in Science.\u0000</p><h3>Methods</h3><p>We have considered the priority rule defined by Robert Merton in 1957, which takes into account the date of acceptance of the report of a discovery in an accredited scientific journal and/or the granting of a patent, complemented by the criteria set out by Ronald Vale and Anthony Hyman (2016) regarding the transfer of information to the scientific community and its validation by it. The awarding of the Nobel Prize in Physiology or Medicine in October 1923 has represented a frame of reference. The claims and disputes regarding the prioritization of the contributions of the main researchers in the organotherapy of diabetes have been analyzed through the study of their scientific production and the debate generated in academic institutions.</p><h3>Main results and conclusions</h3><p>(1) According to the criteria of Merton, Vale and Hyman, the priority of the discovery of the antidiabetic hormone corresponds to the investigations developed in Europe by E. Gley (1900), GL Zülzer (1908) and NC Paulescu (1920). (2) The active principle of the pancreatic extracts developed by Zülzer (acomatol), Paulescu (pancreina) and Banting and Best (insulin) was the same. (3) JB Collip succeeded in isolating the active ingredient from the pancreatic extract in January 1922, eliminating impurities to the point of enabling its use in the clinic. (4) In 1972, the Nobel Foundation modified the purpose of the 1923 Physiology or Medicine award to Banting and Macleod by introducing a new wording: \"the credit for having produced the pancreatic hormone in a practical available form\" (instead of “for the discovery of insulin”).</p></div>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 9","pages":"1241 - 1256"},"PeriodicalIF":3.8,"publicationDate":"2023-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00592-023-02098-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9965935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The correlation between serum uric acid and diabetic kidney disease in adult-onset type 1 diabetes patients in China","authors":"Jun Jiang,&nbsp;Xiaowan Zhou,&nbsp;Lei Lan,&nbsp;Jianping Weng,&nbsp;Wei Ren","doi":"10.1007/s00592-023-02119-7","DOIUrl":"10.1007/s00592-023-02119-7","url":null,"abstract":"<div><h3>Background/aim</h3><p>To assess the correlation between serum uric acid (UA) level and diabetic kidney disease among adult-onset Type 1 diabetes mellitus (T1DM) patients in China.</p><h3>Methods</h3><p>A total of 184 patients with adult-onset T1DM between January 2014 and December 2016 were recruited, with demographics and medical data collected. Comparisons were performed between according to different serum UA gender-specific quartiles. Relationship between serum UA level with urinary ACR and eGFR was also assessed.</p><h3>Results</h3><p>Median urinary ACR and eGFR were 21.55 [10.79, 45.02] mg/g and 113.86 [88.43, 143.61] ml/min/1.73 m², respectively. The median UA was 257.4 (208.2–334.8) μmol/L. Participants with higher serum UA levels had higher urinary ACR and lower eGFR than those with lower UA (<i>P</i> &lt; 0.05). Higher serum UA level was significantly associated with higher urinary ACR in Spearman's correlational analysis (<i>P</i> = 0.006) and multiple stepwise regression analysis (<i>P</i> = 0.013). The association between serum UA and urinary ACR was not linear, but showed a curve correlation, which also showed in the sensitivity analysis. Serum UA in the upper gender-specific quartile, was associated with lower eGFR (<i>P</i> &lt; 0.001) and showed an independent negative correlation with eGFR in multiple stepwise regression analysis (<i>P</i> &lt; 0.001).</p><h3>Conclusions</h3><p>The serum UA level was negatively correlated with eGFR and had a curve correlation with urinary ACR in adult-onset T1DM patients of China.</p></div>","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 9","pages":"1231 - 1239"},"PeriodicalIF":3.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00592-023-02119-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9963271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Orthorexia nervosa and type 1 diabetes: results of a cross‑sectional study","authors":"Claudia Cosentino,&nbsp;Eleonora Rossi,&nbsp;Laura Pala,&nbsp;Romina Lelmi,&nbsp;Campanino Chiara,&nbsp;Valdo Ricca,&nbsp;Edoardo Mannucci,&nbsp;Ilaria Dicembrini,&nbsp;Francesco Rotella","doi":"10.1007/s00592-023-02117-9","DOIUrl":"10.1007/s00592-023-02117-9","url":null,"abstract":"","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 8","pages":"1153 - 1153"},"PeriodicalIF":3.8,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9737863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2023 update on Italian guidelines for the treatment of type 2 diabetes","authors":"Edoardo Mannucci,&nbsp;Riccardo Candido,&nbsp;Lina delle Monache,&nbsp;Marco Gallo,&nbsp;Andrea Giaccari,&nbsp;Maria Luisa Masini,&nbsp;Angela Mazzone,&nbsp;Gerardo Medea,&nbsp;Basilio Pintaudi,&nbsp;Giovanni Targher,&nbsp;Marina Trento,&nbsp;Giuseppe Turchetti,&nbsp;Valentina Lorenzoni,&nbsp;Matteo Monami,&nbsp;for Società Italiana di Diabetologia (SID) and Associazione Medici Diabetologi (AMD)","doi":"10.1007/s00592-023-02107-x","DOIUrl":"10.1007/s00592-023-02107-x","url":null,"abstract":"","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 8","pages":"1119 - 1151"},"PeriodicalIF":3.8,"publicationDate":"2023-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00592-023-02107-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10083801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to letter to Editor on “DIA2PSI” study","authors":"Angelo Emilio Claro,&nbsp;Clelia Palanza,&nbsp;Marianna Mazza,&nbsp;Alessandro Rizzi,&nbsp;Linda Tartaglione,&nbsp;Andrea Corsello,&nbsp;Giuseppe Marano,&nbsp;Giovanna Elsa Ute Muti Schuenemann,&nbsp;Marta Rigoni,&nbsp;Paola Muti,&nbsp;Alfredo Pontecorvi,&nbsp;Luigi Janiri,&nbsp;Gabriele Sani,&nbsp;Dario Pitocco","doi":"10.1007/s00592-023-02116-w","DOIUrl":"10.1007/s00592-023-02116-w","url":null,"abstract":"","PeriodicalId":6921,"journal":{"name":"Acta Diabetologica","volume":"60 8","pages":"1117 - 1118"},"PeriodicalIF":3.8,"publicationDate":"2023-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9687697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}